Breast Cancer

Dr. Vikram Gorantla explains to CURE that staying healthy and managing side effects helps patients with brain metastases remain on therapy.

Losing an online friend to cancer reminded me that grief is real even across screens and that survivor guilt and gratitude can coexist in the same moment.

This patient guide explains triple-positive breast cancer, including treatment options, side effects and more to support informed conversations.

When I was diagnosed with breast cancer, I accepted there would be things I couldn’t completely control.

Dr. Katherine Crew discusses how new HER2-directed therapies are improving survival in metastatic breast cancer.

The treatment of advanced HR+ breast cancer care is evolving, with targeted therapies and clinical trial progress offering a better quality of life.

Dispelling myths and misconceptions and shedding light on disparities in hospice care.

Treatment with the combination of NGC-Cap may increase the cancer-killing power of treatment without adding significant safety concerns.

After beginning treatment for stage 3 inflammatory breast cancer, Lindsey Gunter started experiencing chemotherapy side effects so intense she was unable to walk.

The FDA has approved Enhertu and Perjeta for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

I usually write about my daughter’s cancer, but my friend’s stage 4 breast cancer journey showed me the limits of strength and the need for help.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.

Hormone therapy after breast cancer did not increase risk in BRCA1/2 carriers; estrogen alone was linked to lower risk.

For AYA breast cancer survivors, mobile health intervention was associated with improvements to general and cancer-specific quality of life.

Real and sham acupuncture improved perceived cognitive function versus usual care, with real acupuncture showing greater benefits for objective cognitive outcomes.

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm versus 95.7% in the no MRI arm, researchers reported.

Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.

Adding radiation before surgery with Keytruda increased immune cells in tumors and led to encouraging responses in people with early-stage breast cancer.

Tecentriq numerically increased the rates of chemotherapy-induced ovarian failure compared with chemotherapy alone for patients with triple-negative breast cancer.

Verzenio showed meaningful improvement for some patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 treatment.

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast cancer after initial therapy.

Giredestrant generated improved outcomes over standard endocrine therapy in patients with ER+/HER2–, medium- and high-risk early breast cancer.

Progression-free survival was not statistically significant with Trodelvy versus chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.

After cancer, even your closet tells a story you never imagined living. One quiet afternoon, that story took a hilarious and unexpected turn.